<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns:z="http://www.zotero.org/namespaces/export#"
 xmlns:dcterms="http://purl.org/dc/terms/"
 xmlns:bib="http://purl.org/net/biblio#"
 xmlns:foaf="http://xmlns.com/foaf/0.1/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">
    <bib:Article rdf:about="#item_119">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2079-6382"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Rynkiewich</foaf:surname>
                        <foaf:givenName>Katharina</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Uttla</foaf:surname>
                        <foaf:givenName>Kruthika</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hojat</foaf:surname>
                        <foaf:givenName>Leila</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dc:subject>antimicrobial stewardship</dc:subject>
        <dc:subject>antimicrobial prescribing</dc:subject>
        <dc:subject>practitioner behavior</dc:subject>
        <dc:title>Instant Gratification and Overtreating to Be Safe: Perceptions of U.S. Intensive Care Unit Pharmacists and Residents on Antimicrobial Stewardship.</dc:title>
        <dcterms:abstract>Antimicrobial stewardship programs have been associated with numerous impacts on medical practice including reductions in costs, antimicrobial resistance, and  adverse events. While antimicrobial stewardship is now considered an essential  element of medical practice, the understandings of the value of antimicrobial  stewardship among medical practitioners vary. Additionally, non-physician  practitioners are regularly left out of antimicrobial stewardship interventions  targeting antimicrobial decision-making. Here, we contribute the perspective from  resident physicians and specialists in pharmacy regarding their involvement in  antimicrobial prescribing. Notably, our semi-structured interviews with 10  residents and pharmacy specialists described their limited autonomy in the  clinical setting. However, the participants regularly worked alongside primary  antimicrobial decision-makers and described feeling pressure to overtreat to be  safe. The clear rationales and motivations associated with antimicrobial  prescribing have a noticeable impact on physicians in training and non-physician  practitioners, and as such, we argue that antimicrobial stewardship interventions  targeting primary antimicrobial decision-makers are missing an opportunity to  address the breadth of antimicrobial prescribing culture. By looking at the  perspectives and rationales of physicians in training and non-physician  practitioners, we can see evidence that the act of antimicrobial prescribing is  impacted by individuals on all levels of the hierarchies present in medical  practice.</dcterms:abstract>
        <dc:date>2022 Sep 9</dc:date>
        <z:language>eng</z:language>
        <dc:description>PMID: 36140003 
PMCID: PMC9495149</dc:description>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2079-6382">
        <prism:volume>11</prism:volume>
        <dc:title>Antibiotics (Basel, Switzerland)</dc:title>
        <dc:identifier>DOI 10.3390/antibiotics11091224</dc:identifier>
        <prism:number>9</prism:number>
        <dcterms:alternative>Antibiotics (Basel)</dcterms:alternative>
        <dc:identifier>ISSN 2079-6382</dc:identifier>
    </bib:Journal>
    <bib:Article rdf:about="#item_120">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2049-9361%202049-937X"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hojat</foaf:surname>
                        <foaf:givenName>Leila S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dc:title>Breaking down the barriers to health equity.</dc:title>
        <dc:date>2022 Jan-Dec</dc:date>
        <z:language>eng</z:language>
        <dc:description>PMID: 35186290 
PMCID: PMC8855465</dc:description>
        <bib:pages>20499361221079453</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2049-9361%202049-937X">
        <prism:volume>9</prism:volume>
        <dc:title>Therapeutic advances in infectious disease</dc:title>
        <dc:identifier>DOI 10.1177/20499361221079453</dc:identifier>
        <dcterms:alternative>Ther Adv Infect Dis</dcterms:alternative>
        <dc:identifier>ISSN 2049-9361 2049-937X</dc:identifier>
    </bib:Journal>
    <bib:Article rdf:about="#item_121">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1533-4406%200028-4793"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Falsey</foaf:surname>
                        <foaf:givenName>Ann R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sobieszczyk</foaf:surname>
                        <foaf:givenName>Magdalena E.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hirsch</foaf:surname>
                        <foaf:givenName>Ian</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sproule</foaf:surname>
                        <foaf:givenName>Stephanie</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Robb</foaf:surname>
                        <foaf:givenName>Merlin L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Corey</foaf:surname>
                        <foaf:givenName>Lawrence</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Neuzil</foaf:surname>
                        <foaf:givenName>Kathleen M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hahn</foaf:surname>
                        <foaf:givenName>William</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hunt</foaf:surname>
                        <foaf:givenName>Julie</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mulligan</foaf:surname>
                        <foaf:givenName>Mark J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>McEvoy</foaf:surname>
                        <foaf:givenName>Charlene</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>DeJesus</foaf:surname>
                        <foaf:givenName>Edwin</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hassman</foaf:surname>
                        <foaf:givenName>Michael</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Little</foaf:surname>
                        <foaf:givenName>Susan J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Pahud</foaf:surname>
                        <foaf:givenName>Barbara A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Durbin</foaf:surname>
                        <foaf:givenName>Anna</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Pickrell</foaf:surname>
                        <foaf:givenName>Paul</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Daar</foaf:surname>
                        <foaf:givenName>Eric S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bush</foaf:surname>
                        <foaf:givenName>Larry</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Solis</foaf:surname>
                        <foaf:givenName>Joel</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Carr</foaf:surname>
                        <foaf:givenName>Quito Osuna</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Oyedele</foaf:surname>
                        <foaf:givenName>Temitope</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Buchbinder</foaf:surname>
                        <foaf:givenName>Susan</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cowden</foaf:surname>
                        <foaf:givenName>Jessica</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Vargas</foaf:surname>
                        <foaf:givenName>Sergio L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Guerreros Benavides</foaf:surname>
                        <foaf:givenName>Alfredo</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Call</foaf:surname>
                        <foaf:givenName>Robert</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Keefer</foaf:surname>
                        <foaf:givenName>Michael C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kirkpatrick</foaf:surname>
                        <foaf:givenName>Beth D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Pullman</foaf:surname>
                        <foaf:givenName>John</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tong</foaf:surname>
                        <foaf:givenName>Tina</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Brewinski Isaacs</foaf:surname>
                        <foaf:givenName>Margaret</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Benkeser</foaf:surname>
                        <foaf:givenName>David</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Janes</foaf:surname>
                        <foaf:givenName>Holly E.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Nason</foaf:surname>
                        <foaf:givenName>Martha C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Green</foaf:surname>
                        <foaf:givenName>Justin A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kelly</foaf:surname>
                        <foaf:givenName>Elizabeth J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Maaske</foaf:surname>
                        <foaf:givenName>Jill</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mueller</foaf:surname>
                        <foaf:givenName>Nancy</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shoemaker</foaf:surname>
                        <foaf:givenName>Kathryn</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Takas</foaf:surname>
                        <foaf:givenName>Therese</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Marshall</foaf:surname>
                        <foaf:givenName>Richard P.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Pangalos</foaf:surname>
                        <foaf:givenName>Menelas N.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Villafana</foaf:surname>
                        <foaf:givenName>Tonya</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gonzalez-Lopez</foaf:surname>
                        <foaf:givenName>Antonio</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dc:subject>Adult</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>Aged, 80 and over</dc:subject>
        <dc:subject>Female</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>Male</dc:subject>
        <dc:subject>Middle Aged</dc:subject>
        <dc:subject>Young Adult</dc:subject>
        <dc:subject>Adolescent</dc:subject>
        <dc:subject>*ChAdOx1 nCoV-19/adverse effects</dc:subject>
        <dc:subject>*Vaccine Efficacy</dc:subject>
        <dc:subject>Antibodies, Neutralizing/blood</dc:subject>
        <dc:subject>Antibodies, Viral/blood</dc:subject>
        <dc:subject>Chile/epidemiology</dc:subject>
        <dc:subject>COVID-19/epidemiology/*prevention &amp; control</dc:subject>
        <dc:subject>Double-Blind Method</dc:subject>
        <dc:subject>Immunogenicity, Vaccine</dc:subject>
        <dc:subject>Peru/epidemiology</dc:subject>
        <dc:subject>SARS-CoV-2/immunology</dc:subject>
        <dc:subject>Spike Glycoprotein, Coronavirus/immunology</dc:subject>
        <dc:subject>United States/epidemiology</dc:subject>
        <dc:title>Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.</dc:title>
        <dcterms:abstract>BACKGROUND: The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large, diverse population at increased risk for severe acute respiratory syndrome  coronavirus 2 (SARS-CoV-2) infection in the United States, Chile, and Peru has  not been known. METHODS: In this ongoing, double-blind, randomized,  placebo-controlled, phase 3 clinical trial, we investigated the safety, vaccine  efficacy, and immunogenicity of two doses of AZD1222 as compared with placebo in  preventing the onset of symptomatic and severe coronavirus disease 2019  (Covid-19) 15 days or more after the second dose in adults, including older  adults, in the United States, Chile, and Peru. RESULTS: A total of 32,451  participants underwent randomization, in a 2:1 ratio, to receive AZD1222 (21,635  participants) or placebo (10,816 participants). AZD1222 was safe, with low  incidences of serious and medically attended adverse events and adverse events of  special interest; the incidences were similar to those observed in the placebo  group. Solicited local and systemic reactions were generally mild or moderate in  both groups. Overall estimated vaccine efficacy was 74.0% (95% confidence  interval [CI], 65.3 to 80.5; P&lt;0.001) and estimated vaccine efficacy was 83.5%  (95% CI, 54.2 to 94.1) in participants 65 years of age or older. High vaccine  efficacy was consistent across a range of demographic subgroups. In the fully  vaccinated analysis subgroup, no severe or critical symptomatic Covid-19 cases  were observed among the 17,662 participants in the AZD1222 group; 8 cases were  noted among the 8550 participants in the placebo group (&lt;0.1%). The estimated  vaccine efficacy for preventing SARS-CoV-2 infection (nucleocapsid antibody  seroconversion) was 64.3% (95% CI, 56.1 to 71.0; P&lt;0.001). SARS-CoV-2 spike  protein binding and neutralizing antibodies increased after the first dose and  increased further when measured 28 days after the second dose. CONCLUSIONS:  AZD1222 was safe and efficacious in preventing symptomatic and severe Covid-19  across diverse populations that included older adults. (Funded by AstraZeneca and  others; ClinicalTrials.gov number, NCT04516746.).</dcterms:abstract>
        <dc:date>2021 Dec 16</dc:date>
        <z:language>eng</z:language>
        <dc:rights>Copyright © 2021 Massachusetts Medical Society.</dc:rights>
        <dc:description>PMID: 34587382 
PMCID: PMC8522798</dc:description>
        <bib:pages>2348-2360</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1533-4406%200028-4793">
        <prism:volume>385</prism:volume>
        <dc:title>The New England journal of medicine</dc:title>
        <dc:identifier>DOI 10.1056/NEJMoa2105290</dc:identifier>
        <prism:number>25</prism:number>
        <dcterms:alternative>N Engl J Med</dcterms:alternative>
        <dc:identifier>ISSN 1533-4406 0028-4793</dc:identifier>
    </bib:Journal>
    <bib:Article rdf:about="#item_122">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1537-6591%201058-4838"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hojat</foaf:surname>
                        <foaf:givenName>Leila S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bessesen</foaf:surname>
                        <foaf:givenName>Mary T.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Huang</foaf:surname>
                        <foaf:givenName>Misha</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Reid</foaf:surname>
                        <foaf:givenName>Margaret</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Knepper</foaf:surname>
                        <foaf:givenName>Bryan C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Miller</foaf:surname>
                        <foaf:givenName>Matthew A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shihadeh</foaf:surname>
                        <foaf:givenName>Katherine C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Fugit</foaf:surname>
                        <foaf:givenName>Randolph V.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jenkins</foaf:surname>
                        <foaf:givenName>Timothy C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dc:subject>Humans</dc:subject>
        <dc:subject>antimicrobial stewardship</dc:subject>
        <dc:subject>urinary tract infection</dc:subject>
        <dc:subject>Retrospective Studies</dc:subject>
        <dc:subject>*Bacteremia/drug therapy</dc:subject>
        <dc:subject>*Clostridioides difficile</dc:subject>
        <dc:subject>acute bacterial skin and skin structure infection</dc:subject>
        <dc:subject>Anti-Bacterial Agents/therapeutic use</dc:subject>
        <dc:subject>bacteremia</dc:subject>
        <dc:subject>Cohort Studies</dc:subject>
        <dc:subject>Inpatients</dc:subject>
        <dc:subject>pneumonia</dc:subject>
        <dc:subject>Prospective Studies</dc:subject>
        <dc:subject>Treatment Outcome</dc:subject>
        <dc:title>Effectiveness of Shorter Versus Longer Durations of Therapy for Common Inpatient Infections Associated With Bacteremia: A Multicenter, Propensity-Weighted Cohort  Study.</dc:title>
        <dcterms:abstract>BACKGROUND: National guidelines for pneumonia (PNA), urinary tract infection (UTI), and acute bacterial skin and skin structure infection (ABSSSI) do not  address treatment duration for infections associated with bacteremia. We  evaluated clinical outcomes of patients receiving shorter (5-9 days) versus  longer (10-15 days) duration of antibiotics. METHODS: This was a multicenter  retrospective cohort study of inpatients with uncomplicated PNA, UTI, or ABSSSI  and associated bacteremia. The primary outcome was clinical failure, a composite  of rehospitalization, reinitiation of antibiotics, or all-cause mortality within  30 days of antibiotic completion. Secondary outcomes included individual  components of the primary outcome, Clostridioides difficile infection, and  antibiotic-related adverse effects necessitating change in therapy. A propensity  score-weighted logistic regression model was used to mitigate potential bias  associated with nonrandom assignment of treatment duration. RESULTS: Of 408  patients included, 123 received a shorter treatment duration (median 8 days) and  285 received a longer duration (median 13 days). In the propensity-weighted  analysis, the probability of the primary outcome was 13.5% in the shorter group  and 11.1% in the longer group (average treatment effect, 2.4%; odds ratio [OR],  1.25; 95% confidence interval [CI], .65-2.40; P = .505). However, shorter courses  were associated with higher probability of restarting antibiotics (OR, 1.62; 95%  CI, 1.01-2.61; P = .046) and C. difficile infection (OR, 4.01; 95% CI, 2.21-7.59;  P &lt; .0001). CONCLUSIONS: Shorter courses of antibiotic treatment for PNA, UTI,  and ABSSSI with bacteremia were not associated with increased overall risk of  clinical failure; however, prospective studies are needed to further evaluate the  effectiveness of shorter treatment durations.</dcterms:abstract>
        <dc:date>2020 Dec 15</dc:date>
        <z:language>eng</z:language>
        <dc:rights>© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail:  journals.permissions@oup.com.</dc:rights>
        <dc:description>Place: United States
PMID: 31858136</dc:description>
        <bib:pages>3071-3078</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1537-6591%201058-4838">
        <prism:volume>71</prism:volume>
        <dc:title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</dc:title>
        <dc:identifier>DOI 10.1093/cid/ciz1197</dc:identifier>
        <prism:number>12</prism:number>
        <dcterms:alternative>Clin Infect Dis</dcterms:alternative>
        <dc:identifier>ISSN 1537-6591 1058-4838</dc:identifier>
    </bib:Journal>
    <bib:Article rdf:about="#item_123">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>383</prism:volume>
                <dc:title>The New England journal of medicine</dc:title>
                <dc:identifier>DOI 10.1056/NEJMoa2015301</dc:identifier>
                <prism:number>19</prism:number>
                <dcterms:alternative>N Engl J Med</dcterms:alternative>
                <dc:identifier>ISSN 1533-4406 0028-4793</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Goldman</foaf:surname>
                        <foaf:givenName>Jason D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lye</foaf:surname>
                        <foaf:givenName>David C. B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hui</foaf:surname>
                        <foaf:givenName>David S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Marks</foaf:surname>
                        <foaf:givenName>Kristen M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bruno</foaf:surname>
                        <foaf:givenName>Raffaele</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Montejano</foaf:surname>
                        <foaf:givenName>Rocio</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Spinner</foaf:surname>
                        <foaf:givenName>Christoph D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Galli</foaf:surname>
                        <foaf:givenName>Massimo</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ahn</foaf:surname>
                        <foaf:givenName>Mi-Young</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Nahass</foaf:surname>
                        <foaf:givenName>Ronald G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>Yao-Shen</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>SenGupta</foaf:surname>
                        <foaf:givenName>Devi</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hyland</foaf:surname>
                        <foaf:givenName>Robert H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Osinusi</foaf:surname>
                        <foaf:givenName>Anu O.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cao</foaf:surname>
                        <foaf:givenName>Huyen</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Blair</foaf:surname>
                        <foaf:givenName>Christiana</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wei</foaf:surname>
                        <foaf:givenName>Xuelian</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gaggar</foaf:surname>
                        <foaf:givenName>Anuj</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Brainard</foaf:surname>
                        <foaf:givenName>Diana M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Towner</foaf:surname>
                        <foaf:givenName>William J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Muñoz</foaf:surname>
                        <foaf:givenName>Jose</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mullane</foaf:surname>
                        <foaf:givenName>Kathleen M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Marty</foaf:surname>
                        <foaf:givenName>Francisco M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tashima</foaf:surname>
                        <foaf:givenName>Karen T.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Diaz</foaf:surname>
                        <foaf:givenName>George</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Subramanian</foaf:surname>
                        <foaf:givenName>Aruna</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dc:subject>Adult</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>Female</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>Male</dc:subject>
        <dc:subject>Middle Aged</dc:subject>
        <dc:subject>Treatment Outcome</dc:subject>
        <dc:subject>Adenosine Monophosphate/administration &amp; dosage/adverse effects/*analogs &amp; derivatives</dc:subject>
        <dc:subject>Alanine/administration &amp; dosage/adverse effects/*analogs &amp; derivatives</dc:subject>
        <dc:subject>Antiviral Agents/*administration &amp; dosage/adverse effects</dc:subject>
        <dc:subject>Betacoronavirus</dc:subject>
        <dc:subject>Coronavirus Infections/*drug therapy/mortality/therapy</dc:subject>
        <dc:subject>COVID-19</dc:subject>
        <dc:subject>Drug Administration Schedule</dc:subject>
        <dc:subject>Hospitalization</dc:subject>
        <dc:subject>Oxygen Inhalation Therapy</dc:subject>
        <dc:subject>Pandemics</dc:subject>
        <dc:subject>Pneumonia, Viral/*drug therapy/mortality/therapy</dc:subject>
        <dc:subject>SARS-CoV-2</dc:subject>
        <dc:title>Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.</dc:title>
        <dcterms:abstract>BACKGROUND: Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro and efficacy in animal models of coronavirus disease 2019  (Covid-19). METHODS: We conducted a randomized, open-label, phase 3 trial  involving hospitalized patients with confirmed SARS-CoV-2 infection, oxygen  saturation of 94% or less while they were breathing ambient air, and radiologic  evidence of pneumonia. Patients were randomly assigned in a 1:1 ratio to receive  intravenous remdesivir for either 5 days or 10 days. All patients received 200 mg  of remdesivir on day 1 and 100 mg once daily on subsequent days. The primary end  point was clinical status on day 14, assessed on a 7-point ordinal scale.  RESULTS: In total, 397 patients underwent randomization and began treatment (200  patients for 5 days and 197 for 10 days). The median duration of treatment was 5  days (interquartile range, 5 to 5) in the 5-day group and 9 days (interquartile  range, 5 to 10) in the 10-day group. At baseline, patients randomly assigned to  the 10-day group had significantly worse clinical status than those assigned to  the 5-day group (P = 0.02). By day 14, a clinical improvement of 2 points or more  on the ordinal scale occurred in 64% of patients in the 5-day group and in 54% in  the 10-day group. After adjustment for baseline clinical status, patients in the  10-day group had a distribution in clinical status at day 14 that was similar to  that among patients in the 5-day group (P = 0.14). The most common adverse events  were nausea (9% of patients), worsening respiratory failure (8%), elevated  alanine aminotransferase level (7%), and constipation (7%). CONCLUSIONS: In  patients with severe Covid-19 not requiring mechanical ventilation, our trial did  not show a significant difference between a 5-day course and a 10-day course of  remdesivir. With no placebo control, however, the magnitude of benefit cannot be  determined. (Funded by Gilead Sciences; GS-US-540-5773 ClinicalTrials.gov number,  NCT04292899.).</dcterms:abstract>
        <dc:date>2020 Nov 5</dc:date>
        <z:language>eng</z:language>
        <dc:rights>Copyright © 2020 Massachusetts Medical Society.</dc:rights>
        <dc:description>PMID: 32459919 
PMCID: PMC7377062</dc:description>
        <bib:pages>1827-1837</bib:pages>
    </bib:Article>
    <bib:Article rdf:about="#item_124">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1532-0987%200891-3668"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hojat</foaf:surname>
                        <foaf:givenName>Leila S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Greco</foaf:surname>
                        <foaf:givenName>Peter J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bhardwaj</foaf:surname>
                        <foaf:givenName>Amrita</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bar-Shain</foaf:surname>
                        <foaf:givenName>David</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Abughali</foaf:surname>
                        <foaf:givenName>Nazha</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dc:subject>Female</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>Adolescent</dc:subject>
        <dc:subject>Child</dc:subject>
        <dc:subject>Child, Preschool</dc:subject>
        <dc:subject>Infant</dc:subject>
        <dc:subject>Retrospective Studies</dc:subject>
        <dc:subject>Prospective Studies</dc:subject>
        <dc:subject>*Electronic Health Records</dc:subject>
        <dc:subject>Hepacivirus/genetics/isolation &amp; purification</dc:subject>
        <dc:subject>Hepatitis C/*diagnosis/virology</dc:subject>
        <dc:subject>Mass Screening/*methods</dc:subject>
        <dc:subject>Mothers</dc:subject>
        <dc:subject>Perinatal Care/*statistics &amp; numerical data</dc:subject>
        <dc:subject>Pregnancy</dc:subject>
        <dc:subject>Preventive Health Services/*methods</dc:subject>
        <dc:title>Using Preventive Health Alerts in the Electronic Health Record Improves Hepatitis C Virus Testing Among Infants Perinatally Exposed to Hepatitis C.</dc:title>
        <dcterms:abstract>BACKGROUND: Perinatal exposure to hepatitis C virus (HCV) is a major public health issue, and poor testing rates leave many children with infection  unidentified. We sought to use the electronic health record (EHR) to promote  guideline-directed HCV testing among infants born to mothers with HCV infection  in an urban, safety-net hospital system. METHODS: Our study population was  identified using our EHR database, Epic. Children were included in the study if  they had perinatal HCV exposure, were 18 months to 18 years of age and had at  least 1 encounter in a primary or urgent care clinic during the study period. Our  study included retrospective (October 2011 to February 2015) and prospective  (February 2015 to May 2018) arms. Our EHR-based intervention was initiated in the  prospective arm and recommended a one-time HCV antibody test at or after the age  of 18 months using a health maintenance reminder. The health maintenance reminder  activated a point-of-care alert and a linked HCV testing order set in all  prespecified encounters during the intervention period. RESULTS: Median time to  appropriate HCV testing decreased from 96.2 months preintervention to 9.1 months  postintervention (P &lt; 0.0001), and rate of completed antibody testing increased  from 14% to 61% (P &lt; 0.0001). CONCLUSIONS: Among children with perinatal HCV  exposure, using a point-of-care alert within the EHR significantly increased the  HCV antibody testing rate in accordance with American Academy of Pediatrics (AAP)  recommendations. More effective EHR-based interventions combined with increased  provider awareness of appropriate HCV testing in perinatally exposed infants is  imperative.</dcterms:abstract>
        <dc:date>2020 Oct</dc:date>
        <z:language>eng</z:language>
        <dc:description>Place: United States
PMID: 32453202</dc:description>
        <bib:pages>920-924</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1532-0987%200891-3668">
        <prism:volume>39</prism:volume>
        <dc:title>The Pediatric infectious disease journal</dc:title>
        <dc:identifier>DOI 10.1097/INF.0000000000002757</dc:identifier>
        <prism:number>10</prism:number>
        <dcterms:alternative>Pediatr Infect Dis J</dcterms:alternative>
        <dc:identifier>ISSN 1532-0987 0891-3668</dc:identifier>
    </bib:Journal>
    <bib:Article rdf:about="#item_125">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2214-2509"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Dousa</foaf:surname>
                        <foaf:givenName>Khalid M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Malavade</foaf:surname>
                        <foaf:givenName>Sharad S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Furin</foaf:surname>
                        <foaf:givenName>Jennifer</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gripshover</foaf:surname>
                        <foaf:givenName>Barbara</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hatszegi</foaf:surname>
                        <foaf:givenName>Marjorie</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hojat</foaf:surname>
                        <foaf:givenName>Leila</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Saade</foaf:surname>
                        <foaf:givenName>Elie</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Salata</foaf:surname>
                        <foaf:givenName>Robert A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dc:subject>SARS-CoV-2</dc:subject>
        <dc:subject>COVID19</dc:subject>
        <dc:subject>Hydroxychloroquine</dc:subject>
        <dc:subject>Pandemic</dc:subject>
        <dc:title>SARS-CoV-2 infection in a patient on chronic hydroxychloroquine therapy: Implications for prophylaxis.</dc:title>
        <dcterms:abstract>People exposed to COVID-19 have a risk of developing disease, and health care workers are at risk at a time when they are badly needed during a health care  crisis. Hydroxychloroquine and chloroquine have been used as treatment and are  being considered as prophylaxis. Our patient developed COVID-19 while on  hydroxychloroquine and although more work is needed, this calls into question the  role of these medications as preventive therapy.</dcterms:abstract>
        <dc:date>2020</dc:date>
        <z:language>eng</z:language>
        <dc:rights>© 2020 The Author(s).</dc:rights>
        <dc:description>PMID: 32341910 
PMCID: PMC7185003</dc:description>
        <bib:pages>e00778</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2214-2509">
        <prism:volume>20</prism:volume>
        <dc:title>IDCases</dc:title>
        <dc:identifier>DOI 10.1016/j.idcr.2020.e00778</dc:identifier>
        <dcterms:alternative>IDCases</dcterms:alternative>
        <dc:identifier>ISSN 2214-2509</dc:identifier>
    </bib:Journal>
    <bib:Article rdf:about="#item_126">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1525-1497%200884-8734"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hojat</foaf:surname>
                        <foaf:givenName>Leila</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Avery</foaf:surname>
                        <foaf:givenName>Ann</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Greco</foaf:surname>
                        <foaf:givenName>Peter J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kaelber</foaf:surname>
                        <foaf:givenName>David C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dc:subject>Adult</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>*Hepacivirus</dc:subject>
        <dc:subject>*Hepatitis C/diagnosis/epidemiology</dc:subject>
        <dc:subject>electronic health records</dc:subject>
        <dc:subject>Electronic Health Records</dc:subject>
        <dc:subject>hepatitis C virus</dc:subject>
        <dc:subject>Mass Screening</dc:subject>
        <dc:subject>personal health records</dc:subject>
        <dc:subject>population health management</dc:subject>
        <dc:subject>Primary Health Care</dc:subject>
        <dc:subject>screening</dc:subject>
        <dc:title>Doubling Hepatitis C Virus Screening in Primary Care Using Advanced Electronic Health Record Tools-A Non-Randomized Controlled Trial.</dc:title>
        <dcterms:abstract>BACKGROUND: Hepatitis C virus (HCV) infection is a major public health burden, affecting over 4 million people. The Centers for Disease Control and Prevention  and the US Preventive Services Task Force guidelines recommend screening everyone  born between 1945 and 1965, but screening rates remain low. OBJECTIVE: To  determine whether bulk ordering and electronic messaging to patients improves  guideline-based HCV screening rates. DESIGN: A non-randomized controlled trial of  1024 adults from November 2016 to March 2017. PARTICIPANTS: Patients due for HCV  screening with at least one primary care office visit in one of three primary  care clinics and enrolled in the healthcare system's tethered personal health  record (tPHR). INTERVENTIONS: Control patients received normal care for HCV  screening, consisting of passive HCV reminders to providers during face-to-face  visits and passive HCV screening notification through the patient's tPHR.  Intervention patients received normal care and also had HCV antibody tests  ordered for them and customized messages sent through their tPHR inviting them to  go directly to the lab for HCV screening over a 12-week period. MAIN MEASURES:  Percentage/number of patients receiving HCV antibody tests during the  intervention period. Percentage/number of intervention group patients receiving  HCV screening with other blood work. KEY RESULTS: In the intervention group, 33%  (168 of 514) completed HCV testing, compared with 19% (97 of 510) of controls (OR  1.7, 95% CI 1.2-2.1). Bulk lab ordering appeared to have a large impact while  bulk messaging appeared to have a less significant role. CONCLUSIONS: Leveraging  population analytics and bulk ordering in an electronic health record with bulk  messaging to a tPHR directly engages patients in blood screening tests and can  significantly improve completion. This methodology has a broad range of  applications including many recommended screening or disease-specific testing.  This bulk ordering and direct-to-patient messaging approach improves patient  screening while decreasing provider/staff work. TRIAL REGISTRATION: MetroHealth  IRB16-00776 (ClinicalTrials.gov).</dcterms:abstract>
        <dc:date>2020 Feb</dc:date>
        <z:language>eng</z:language>
        <dc:description>PMID: 31792863 
PMCID: PMC7018893</dc:description>
        <bib:pages>498-504</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1525-1497%200884-8734">
        <prism:volume>35</prism:volume>
        <dc:title>Journal of general internal medicine</dc:title>
        <dc:identifier>DOI 10.1007/s11606-019-05536-z</dc:identifier>
        <prism:number>2</prism:number>
        <dcterms:alternative>J Gen Intern Med</dcterms:alternative>
        <dc:identifier>ISSN 1525-1497 0884-8734</dc:identifier>
    </bib:Journal>
    <bib:Article rdf:about="#item_127">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2090-6625%202090-6633"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Motoa</foaf:surname>
                        <foaf:givenName>Gabriel</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Pate</foaf:surname>
                        <foaf:givenName>Amy</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Franco-Paredes</foaf:surname>
                        <foaf:givenName>Carlos</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chastain</foaf:surname>
                        <foaf:givenName>Daniel B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Henao-Martínez</foaf:surname>
                        <foaf:givenName>Andrés F.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hojat</foaf:surname>
                        <foaf:givenName>Leila</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dc:title>Use of Procalcitonin to Guide Discontinuation of Antimicrobial Therapy in Patients with Persistent Intra-Abdominal Collections: A Case Series.</dc:title>
        <dcterms:abstract>OBJECTIVE: Limited evidence exists for the use of procalcitonin (PCT) to guide the duration of antimicrobial therapy in patients with intra-abdominal abscesses  (IAA). In this case series, we describe clinical presentations and outcomes using  PCT to guide cessation of antimicrobial therapy in patients with persistent IAA  who exhibited clinical improvement. METHODS: A retrospective analysis of patients  with IAA who had PCT levels available to review was performed in a tertiary  academic teaching institution in the United States between 2017 and 2018.  Demographics, clinical characteristics, and outcomes were obtained from the  medical records. Patients were followed up for a minimum of 180 days after  completion of antimicrobial therapy to determine if evidence of recurrence or  mortality was present. RESULTS: We identified four patients with IAA. They  underwent early drainage of the source of infection and received empiric  antimicrobial therapy according to individual risk factors and clinical  scenarios. Antimicrobials were discontinued after clinical and radiographic  improvement and evidence of normal PCT levels, regardless of the persistence of  fluid collections. No evidence of recurrence or mortality was observed during the  follow-up period. CONCLUSIONS: We found PCT to be a useful aid in the medical  decision-making process to safely discontinue antimicrobial therapy in a series  of patients with persistent intra-abdominal collections despite early drainage  and appropriate course of antimicrobial therapy.</dcterms:abstract>
        <dc:date>2020</dc:date>
        <z:language>eng</z:language>
        <dc:rights>Copyright © 2020 Gabriel Motoa et al.</dc:rights>
        <dc:description>PMID: 32158570 
PMCID: PMC7060429</dc:description>
        <bib:pages>6342180</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2090-6625%202090-6633">
        <prism:volume>2020</prism:volume>
        <dc:title>Case reports in infectious diseases</dc:title>
        <dc:identifier>DOI 10.1155/2020/6342180</dc:identifier>
        <dcterms:alternative>Case Rep Infect Dis</dcterms:alternative>
        <dc:identifier>ISSN 2090-6625 2090-6633</dc:identifier>
    </bib:Journal>
    <bib:Article rdf:about="#item_128">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2196-3045"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hojat</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tobolowsky</foaf:surname>
                        <foaf:givenName>F.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Franco-Paredes</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dc:subject>Cutaneous</dc:subject>
        <dc:subject>Municipal water systems</dc:subject>
        <dc:subject>Mycobacterium kansasii</dc:subject>
        <dc:subject>Pulmonary</dc:subject>
        <dc:subject>Skin and soft tissue infections</dc:subject>
        <dc:title>Cutaneous Manifestations of Mycobacterium kansasii Infection.</dc:title>
        <dcterms:abstract>PURPOSE OF REVIEW: Mycobacterium kansasii is a slow-growing member of the nontuberculous mycobacterial species that manifests clinically with pulmonary,  cutaneous, or disseminated forms. Most cases of M. kansasii infection occur in  immunocompromised hosts including HIV/AIDS, solid-organ transplantation,  anti-interferon-γ antibody disorder, or among those with pulmonary disorders such  as chronic obstructive pulmonary disease or cystic fibrosis. In this review, we  aim to discuss relevant literature regarding the clinical manifestations of this  infection with a particular emphasis on the clinical spectrum and treatment of  the cutaneous manifestations of this mycobacterial infection. RECENT FINDINGS:  Infection caused by M. kansasii is associated with exposure to contaminated  municipal water systems since this organism thrives in human-engineered  environments. Chronic or subacute skin lesions may represent the primary source  of entry of the organism due to open sores or traumatic injuries. Alternatively,  cutaneous lesions may occur secondary to dissemination of the organism to the  skin from pulmonary infection. The diagnosis of M. kansasii of the skin and soft  tissues should be entertained among immunocompetent or immunocompromised  individuals presenting with subacute or chronic lesions. The differential  diagnosis of M. kansasii infection includes infections of skin and soft tissues  caused by rapidly growing mycobacteria, subcutaneous mycosis, pyogenic bacterial  infections, nocardiosis, free-living amoebas, and protothecosis. SUMMARY:  Cutaneous lesions caused by M. kansasii most commonly manifest in the setting of  concomitant pulmonary disease or in the setting of disseminated infection among  immunocompromised hosts. When clinicians suspect a cutaneous mycobacterial  infection either due to slow-growing mycobacteria such as M. kansasii or due to  rapidly growing mycobacteria, obtaining a skin biopsy of chronic nonhealing  lesions for histopathologic evaluation and for microbiological assessment is  crucial. Mycobacteriology assessment of clinical specimen includes acid-fast  bacilli staining, culture in solid/liquid media, and molecular assays for  confirmation. Treatment of M. kansasii infection of the skin and subcutaneous  tissues follows the same management recommendations as those for the treatment of  isolated pulmonary forms or disseminated disease.</dcterms:abstract>
        <dc:date>2018 Dec</dc:date>
        <z:language>eng</z:language>
        <dc:description>PMID: 35663919 
PMCID: PMC9164248</dc:description>
        <bib:pages>224-227</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2196-3045">
        <prism:volume>5</prism:volume>
        <dc:title>Current tropical medicine reports</dc:title>
        <dc:identifier>DOI 10.1007/s40475-018-0160-8</dc:identifier>
        <prism:number>4</prism:number>
        <dcterms:alternative>Curr Trop Med Rep</dcterms:alternative>
        <dc:identifier>ISSN 2196-3045</dc:identifier>
    </bib:Journal>
    <bib:Article rdf:about="#item_129">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1938-2707%200009-9228"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hojat</foaf:surname>
                        <foaf:givenName>Leila</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Schweiger</foaf:surname>
                        <foaf:givenName>Michelle</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dc:subject>Humans</dc:subject>
        <dc:subject>Male</dc:subject>
        <dc:subject>Child</dc:subject>
        <dc:subject>*Mosaicism</dc:subject>
        <dc:subject>Body Height/physiology</dc:subject>
        <dc:subject>Growth Disorders/*complications/drug therapy/physiopathology</dc:subject>
        <dc:subject>Growth Hormone/therapeutic use</dc:subject>
        <dc:subject>hypothyroidism</dc:subject>
        <dc:subject>Hypothyroidism/*complications/drug therapy/physiopathology</dc:subject>
        <dc:subject>mosaicism</dc:subject>
        <dc:subject>short stature</dc:subject>
        <dc:subject>Thyroxine/therapeutic use</dc:subject>
        <dc:title>45,X/46,XY Mosaicism and Possible Association With Hypothyroidism in Males.</dc:title>
        <dcterms:abstract>Mosaicism has a wide phenotypic spectrum but frequently manifests as the normal male phenotype. Its association with short stature has been well recognized and  appears to respond effectively to growth hormone therapy. We present 2  phenotypically normal males who both initially presented with short stature and  were found to have hypothyroidism. They were treated for hypothyroidism but their  growth did not improve as expected. Further testing revealed 45,X/46,XY mosaicism  in both males. We propose that a potential link exists between 45,X/46,XY  mosaicism and hypothyroidism, which has not been previously described in the  literature. Furthermore, it may be beneficial to evaluate for other disorders  such as 45,X/46,XY mosaicism in young males with short stature and hypothyroidism  if their growth does not improve once they become euthyroid.</dcterms:abstract>
        <dc:date>2016 Jun</dc:date>
        <z:language>eng</z:language>
        <dc:rights>© The Author(s) 2015.</dc:rights>
        <dc:description>Place: United States
PMID: 26294759</dc:description>
        <bib:pages>549-551</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1938-2707%200009-9228">
        <prism:volume>55</prism:volume>
        <dc:title>Clinical pediatrics</dc:title>
        <dc:identifier>DOI 10.1177/0009922815600439</dc:identifier>
        <prism:number>6</prism:number>
        <dcterms:alternative>Clin Pediatr (Phila)</dcterms:alternative>
        <dc:identifier>ISSN 1938-2707 0009-9228</dc:identifier>
    </bib:Journal>
</rdf:RDF>
